USFDA23 Dec 2025, 06:21 pm
Emcure Pharmaceuticals' Kadu Facility Receives 'No Action Indicated' Classification from US FDA Inspection
AI Summary
Emcure Pharmaceuticals Ltd. has announced that their manufacturing facility located at Kadu, Surendranagar, Gujarat, India, has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA). The US FDA has classified the inspection of the facility as 'No Action Indicated' (NAI), indicating that no objectionable conditions or practices were found during the inspection.
Key Highlights
- Emcure Pharmaceuticals' Kadu facility received an Establishment Inspection Report (EIR) from the US FDA.
- The US FDA has classified the inspection of the facility as 'No Action Indicated' (NAI).
- This classification indicates that no objectionable conditions or practices were found during the inspection.
- This is a positive development for Emcure Pharmaceuticals, reflecting their commitment to quality and compliance.